Gujarat: PM Modi reviews vaccine development at Zydus Cadila facility

AHMEDABAD: Prime Minister Narendra Modi on Saturday began his three-city visit to review coronavirus vaccine development work by going to pharma major Zydus Cadila’s manufacturing facility near Ahmedabad. Wearing a PPE kit, Modi reviewed the vaccine development process at the Zydus Cadila research centre in Changodar industrial area, over 20 km from Ahmedabad.

After his arrival at Ahmedabad airport from Delhi shortly after 9 am, Modi flew to the Zydus Cadila plant and held discussions with the promoters and executives of the company, an official said.

Modi spent over an hour at the plant, before leaving for the airport, from where will fly to Hyderabad.

Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August.

In Hyderabad, Modi is scheduled to visit vaccine maker Bharat Biotech’s facility.

After landing at Hakimpet Air Force station, Modi will reach Bharat Biotech’s facility at Genome Valley at 1.30 pm. The facility is around 50 km from Hyderabad.

Bharat Biotech’s Covaxin is undergoing phase-3 trials.

After his hour-long visit to the facility, the PM will proceed to Pune, where he will visit the Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and the Oxford University for the vaccine.

The prime minister will reach Serum Institute campus around 4.30 pm, an official said.

Modi’s hour-long visit to SII is aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanism, he said.

The PM will fly back to Delhi in the evening, the official said.

  • Related Posts

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    New Delhi: The Delhi Police Crime Branch has busted a major interstate syndicate allegedly involved in the illegal procurement, diversion, storage, repackaging and sale of counterfeit and illegally obtained high-value…

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    New Delhi:  Indian researchers have developed an experimental “smart” cancer drug designed to remain largely inactive in healthy tissues and activate primarily inside cancer cells, potentially reducing the severe side…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case